AlzeCure publishes its interim report for January - September 2026
STOCKHOLM, SE / ACCESS Newswire / November 11, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its interim report for the period January - September 2026 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"The third quarter of 2026 marked a breakthrough for AlzeCure. On July 1, we entered into our second major collaboration and out-licensing agreement, this time with QuantumCell ApS for NeuroRestore, our Alzheimer's and cognition project. The agreement has a potential value of USD 2.2 billion, excluding royalties. Just three weeks earlier, we signed a major agreement with Eli Lilly that had a potential value of over USD 1 billion, also excluding royalties. Together, the agreements rank among the largest biotech deals in Swedish history. To me, they are clear proof of the quality of our projects and the strength of our organization. The agreements now make it possible to accelerate the other projects in our portfolio."
Johan Sandin, CEO of AlzeCure Pharma AB
Financial information for July - September 2026, Group
Figures in parentheses refer to the corresponding period of the previous year.
Financial information for January - September 2026, Group
Figures in parentheses refer to the corresponding period of the previous year.
Significant events during the period July - September 2026
Significant events during the period January - June 2026
Significant events after the end of the period
The full report is attached as PDF and is available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
For more information, please contact
Johan Sandin, CEO
Tel: +46(0)70 373 88 24
[email protected]
About AlzeCure Pharma AB (publ)
AlzeCure ® is a Swedish biotech company developing new, innovative drug therapies for severe diseases and conditions affecting the central nervous system, such as Alzheimer's disease and pain - indications where available treatment options today are very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several drug candidates in parallel based on three research platforms: NeuroRestore ®, Alzstatin ® and Painless. AlzeCure has recently signed collaboration and outlicensing agreements with Eli Lilly on the Alzstatin platform, and with QuantumCell ApS on the NeuroRestore platform.
FNCA Sweden AB is the company's Certified Adviser. For more information, visit www.alzecurepharma.com
Attachments
Alzecure Q3 2026 ENG
SOURCE: AlzeCure Pharma